Literature DB >> 28146269

The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study.

Faraz Kureshi1,2, Ali Shafiq1,2, Suzanne V Arnold1,2, Kensey Gosch1, Tracie Breeding1, Ashwath S Kumar2, Philip G Jones1, John A Spertus1,2.   

Abstract

Although eliminating angina is a primary goal in treating patients with chronic coronary artery disease (CAD), few contemporary data quantify prevalence and severity of angina across US cardiology practices. The authors hypothesized that angina among outpatients with CAD managed by US cardiologists is low and its prevalence varies by site. Among 25 US outpatient cardiology clinics enrolled in the American College of Cardiology Practice Innovation and Clinical Excellence (PINNACLE) registry, we prospectively recruited a consecutive sample of patients with chronic CAD over a 1- to 2-week period at each site between April 2013 and July 2015, irrespective of the reason for their appointment. Eligible patients had documented history of CAD (prior acute coronary syndrome, prior coronary revascularization procedure, or diagnosis of stable angina) and ≥1 prior office visit at the practice site. Angina was assessed directly from patients using the Seattle Angina Questionnaire Angina Frequency score. Among 1257 patients from 25 sites, 7.6% (n = 96) reported daily/weekly, 25.1% (n = 315) monthly, and 67.3% (n = 846) no angina. The proportion of patients with daily/weekly angina at each site ranged from 2.0% to 24.0%, but just over half (56.3%) were on ≥2 antianginal medications, with wide variability across sites (0%-100%). One-third of outpatients with chronic CAD managed by cardiologists report having angina in the prior month, and 7.6% have frequent symptoms. Among those with frequent angina, just over half were on ≥2 antianginal medications, with wide variability across sites. These findings suggest an opportunity to improve symptom control.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ischemic heart disease; angina; chronic

Mesh:

Year:  2016        PMID: 28146269      PMCID: PMC5300688          DOI: 10.1002/clc.22628

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  25 in total

Review 1.  Clinical practice. Chronic stable angina.

Authors:  Jonathan Abrams
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

2.  Medication Discussion Questions (MedDQ): developing a guide to facilitate patient-clinician communication about heart medications.

Authors:  Linda Garavalia; Brian Garavalia; John A Spertus; Carole Decker
Journal:  J Cardiovasc Nurs       Date:  2011 Jul-Aug       Impact factor: 2.083

3.  The Improving Continuous Cardiac Care (IC(3)) program and outpatient quality improvement.

Authors:  Paul S Chan; William J Oetgen; John A Spertus
Journal:  Am J Med       Date:  2010-03       Impact factor: 4.965

4.  The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina.

Authors:  Caroline A Daly; Felicity Clemens; Jose L Lopez Sendon; Luigi Tavazzi; Eric Boersma; Nicholas Danchin; Francois Delahaye; Anselm Gitt; Desmond Julian; David Mulcahy; Witold Ruzyllo; Kristian Thygesen; Freek Verheugt; Kim M Fox
Journal:  Eur Heart J       Date:  2005-03-18       Impact factor: 29.983

Review 5.  Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution.

Authors:  Adam D Timmis; Gene Feder; Harry Hemingway
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

6.  The Global Registry of Acute Coronary Events, 1999 to 2009--GRACE.

Authors:  K A A Fox; K A Eagle; J M Gore; Ph G Steg; F A Anderson
Journal:  Heart       Date:  2010-05-29       Impact factor: 5.994

7.  The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study.

Authors:  John F Beltrame; Andrew J Weekes; Claire Morgan; Rosanna Tavella; John A Spertus
Journal:  Arch Intern Med       Date:  2009-09-14

8.  Incidence and prognostic implications of stable angina pectoris among women and men.

Authors:  Harry Hemingway; Alison McCallum; Martin Shipley; Kristiina Manderbacka; Pekka Martikainen; Ilmo Keskimäki
Journal:  JAMA       Date:  2006-03-22       Impact factor: 56.272

9.  Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting.

Authors:  Francine C Wiest; Chris L Bryson; Marcia Burman; Mary B McDonell; Jorja G Henikoff; Stephan D Fihn
Journal:  Am J Med       Date:  2004-08-15       Impact factor: 4.965

10.  A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction.

Authors:  Eric D Peterson; Matthew T Roe; John S Rumsfeld; Richard E Shaw; Ralph G Brindis; Gregg C Fonarow; Christopher P Cannon
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-09
View more
  10 in total

Review 1.  Using Patient-Reported Outcomes toAssess Healthcare Quality: Toward Better Measurement of Patient-Centered Care in Cardiovascular Disease.

Authors:  Raul Angel Garcia; John A Spertus
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-04-05

2.  Health-related quality of life and associated factors in patients with myocardial infarction after returning to work: a cross-sectional study.

Authors:  Ruofei Du; Panpan Wang; Lixia Ma; Leon M Larcher; Tao Wang; Changying Chen
Journal:  Health Qual Life Outcomes       Date:  2020-06-17       Impact factor: 3.186

3.  Correlation between exercise, personal income level and health-related quality of life in patients with newly diagnosed stable angina.

Authors:  Yi Wang; Lei Huang; Lai-Xin Zhou
Journal:  Mil Med Res       Date:  2019-11-25

4.  Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease.

Authors:  Daniel M Blumenthal; Sidney E Howard; Jennifer Searl Como; Sandra M O'Keefe; Steven J Atlas; Daniel M Horn; Neil W Wagle; Jason H Wasfy; Robert W Yeh; Joshua P Metlay
Journal:  JAMA Netw Open       Date:  2021-06-01

5.  Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study.

Authors:  Alexander C Fanaroff; Lisa A Kaltenbach; Eric D Peterson; Connie N Hess; David J Cohen; Gregg C Fonarow; Tracy Y Wang
Journal:  J Am Heart Assoc       Date:  2017-10-19       Impact factor: 5.501

6.  Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris.

Authors:  Yuri M Pozdnyakov
Journal:  Cardiol Ther       Date:  2018-05-19

7.  Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study.

Authors:  Leonardo De Luca; Pier Luigi Temporelli; Donata Lucci; Furio Colivicchi; Paolo Calabrò; Carmine Riccio; Antonio Amico; Franco Mascia; Emanuele Proia; Andrea Di Lenarda; Michele Massimo Gulizia
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

8.  Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice.

Authors:  Maria G Glezer; Vladimir A Vygodin
Journal:  Adv Ther       Date:  2018-08-13       Impact factor: 3.845

9.  Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study.

Authors:  Yuri Lopatin; Parvoleta Petrova
Journal:  Cardiol Ther       Date:  2021-12-27

Review 10.  Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment.

Authors:  Leonardo De Luca; Giuseppe M C Rosano; Ilaria Spoletini
Journal:  Cardiol J       Date:  2021-04-12       Impact factor: 3.487

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.